Xeltis’ proprietary ETR technology harnesses the body’s natural healing processes, enabling the development of functional, living new vessels and heart valves that grow and remodel over time. Xeltis creates groundbreaking implants that support the natural formation of durable, living vessels, addressing significant unmet needs for millions of patients requiring vascular therapy. Relevant markets—including end-stage kidney disease (dialysis) with aXess, coronary disease with Xabg, and peripheral arterial disease with Xpad—are collectively worth over USD 10 billion.